Zimmer Biomet Holdings Stock News

Zimmer (ZBH) delivered earnings and revenue surprises of -0.51% and 0.64%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

According to Zimmer Biomet (ZBH), both Q4 net sales and earnings metrics are negatively impacted by China VBP in Knees, Hips and S.E.T. product categories.

Pre-open movers U.S. stock futures traded lower in early pre-market trade after the Nasdaq jumped more than 200 points in the previous session. Investors are awaiting earnings results from Tyson Food

Some of the stocks that may grab inve3stor focus today are: Wall Street expects Tyson Foods, Inc. (NYSE: TSN) to report quarterly earnings at $1.90 per share on revenue of $12.18 billion after the c

Zimmer (ZBH) delivered earnings and revenue surprises of -0.51% and 0.64%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zimmer Biomet Holdings Inc's  ZBH Q4 sales decreased by 2.3% Y/Y to $2.04 billion (down 0.8% on a constant currency basis), missing the Street estimate of $2.07 billion. Get the Inside Access Trade

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.

Zimmer Biomet (NYSE:ZBH) is scheduled to announce Q4 earnings results on Monday, February 7th, before market open.The consensus EPS Estimate is $1.98 (-6.2% Y/Y) and the consensus

Mr. David Dvorak, previously the President and CEO of Zimmer Biomet, brings a 25+ year proven track record of executive leadership, operating experience, and board memberships Dr. Gregory Berk joins with 30+ years of medical experience with oncology expertise in clinical trials, drug development, and regulatory strategy in both industry and academia GARDEN CITY, N.Y., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR ), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced the appointments of Mr. David Dvorak and Dr. Gregory Berk to Beyond Cancer''s Board of Directors. Following these appointments, the Beyond Cancer Board of Directors will be comprised of six members with no further additions planned.

Zimmer Biomet <> is trading lower after UBS downgraded the maker of musculoskeletal products to Neutral from Buy, noting, among other things, COVID-driven pressure on

Upgrades Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09 in the year-ago quarter. At

Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zimmer Biomet (ZBH) struggles to sustain the recovery trend in the second half of 2021.

Zimmer Biomet (ZBH) struggles to sustain the recovery trend in the second half of 2021.